Roxithromycin in skin and soft tissue infections.
In a double blind randomised investigation in 76 patients, roxithromycin (150 mg bd) and doxycycline (200 mg once daily) were compared in two groups of patients who were well-matched for age, sex, body weight, diagnosis, duration and severity of disease and associated pathological conditions, with infected skin conditions. Clinical effectiveness was 92% for roxithromycin and 82% for doxycycline, and bacteriological effectiveness also 92% and 82% respectively, the differences not being statistically significant.
Agache
P
P
University Department of Dermatology, Hôpital St-Jacques, Besançon, France.
Amblard
P
P
Moulin
G
G
Barrière
H
H
Texier
L
L
Beylot
C
C
Bergoend
H
H
D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004318:Doxycycline / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005602:France; D006801:Humans; D007933:Leucomycins / Q000009:adverse effects / Q000627:therapeutic use*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012874:Skin Diseases, Infectious / Q000188:drug therapy* / Q000382:microbiology
D007933:Leucomycins; D004318:Doxycycline